Search results
Added:
1 year ago
ESC 2024 - We are joined by Dr Michelle Kittleson (Cedars-Sinai Heart Institute, US) for a concise and insightful summary of the hot-line and late-breaking data that is expected to have an impact on heart failure care.Trials covered in detail include:FINEARTS HFHELIOS-BRESHAPE HF2Recorded remotely from Los Angeles, 2024.Editors: Jordan Rance and Mirjam Boros.Videographers: Mike Knight, Dan Brent,…
View more
Start date:
Feb 25, 2025
End date:
Feb 26, 2025
Due to the recent success of New Horizons in Amyloidosis, Radcliffe Cardiology are excited to introduce a new 2-day event ‘New Horizons in Cardiomyopathy’ (NHC) in February 2025.The event, hosted on Radcliffe Cardiology, will be streamed on Tuesday 25 February - Wednesday 26February 2025. It promises an interactive and informative experience, updating professionals on cardiac amyloidosis and…
View more
Added:
4 months ago
Source:
Radcliffe Cardiology
New findings from a large, international registry suggest that in patients with the dual pathology of aortic stenosis and transthyretin-associated cardiac amyloidosis, a combination of aortic valve replacement and disease-specific medication offers the most significant survival benefit.¹ The study (NCT06129331) aimed to clarify the prognostic impact of these treatments in this increasingly…
View more
SGLT-2 Inhibitors and Heart Failure
Added:
1 year ago
Review Article
Added:
1 year ago
ESC Congress 24 – Day 1 of the ESC Congress 2024 was filled with excitement as new clinical practice guidelines were unveiled, along with several highly anticipated Hot Line trials.Interventional experts Dr Mirvat Alasnag and Dr Khaled Al-Shaibi (King Fahd Armed Forces Hospital, SA) are concluding the first day by providing practical summaries of the key guidelines and offering critical insights…
View more
Added:
5 months ago
AHA Scientific Sessions 2025 – MAPLE-HCM responder analysis shows aficamten monotherapy led to greater treatment effect when compared to metoprolol monotherapy.Dr Andrew Wang (Duke University Medical Center, Durham, NC, US) presents a responder analysis from the MAPLE-HCM trial (NCT05767346), examining clinical responses to aficamten monotherapy versus metoprolol in patients with obstructive…
View more
Added:
6 months ago
Navigate the rapidly evolving treatment landscape for hypertrophic cardiomyopathy with Dr Anjali Tiku Owens, a renowned expert in inherited cardiovascular diseases and advanced heart failure.This comprehensive presentation, part of the Cardiomyopathies track of Women As One's CLIMB® 2025 Skills Training Program, explores both established and emerging therapeutic approaches for obstructive and non…
View more
Added:
6 months ago
Master the diagnostic complexities of hypertrophic cardiomyopathy (HCM) with Dr Sara Saberi, a leading expert in inherited cardiovascular diseases.This comprehensive presentation, part of the Cardiomyopathies track of Women As One's CLIMB® 2025 Skills Training Program, provides essential insights into the nuanced approach required for accurate HCM diagnosis and risk stratification.Dr Saberi…
View more
Added:
1 year ago
AHA Conference 2024 - 22 month data from the risk evaluation and mitigation strategy (REMS) program for mavacamten (Camzyos; Bristol-Myers Squibb Company) in hypertrophic cardiomyopathy (HCM) patients.Dr Milind Desai (Cleveland Clinic, Ohio, US) joins us onsite at AHA Conference to discuss the findings from the REMS program for mavacamten.The REMS program investigated the safety and efficacy of…
View more
Added:
5 months ago
HFSA 25 - Aficamten improves excercise capacity compared to metoprolol in patients with obstructive hypertrophic cardiomyopathy in a prespecified analysis of the MAPLE-HCM study.Dr Gregory Lewis joins us to discuss findings from a prespecified cardiopulmonary exercise testing analysis of the MAPLE-HCM trial, which reveals divergent effects between aficamten and metoprolol on exercise performance…
View more